The research aims to confirm the anti-tumor effects exerted by VNP20009-AbVec-Igκ-MIIP and to explore new breakthroughs for the challenges faced by current ovarian cancer drug treatment, such as drug resistance, low specificity, and side effects. The gene discussed is MIIP; the disease is ovarian carcinoma.